“Clinical characteristics, response to prior therapies, and response to dupilumab” were assessed in three patients with diagnosed hand eczema.
Each patient experienced positive results after two weeks of taking dupilumab which deems the drug a suitable therapeutic option for patients who have palmar hand eczema and meet the diagnostic criteria of atopic dermatitis.
Learn more about this study at the Journal of the American Academy of Dermatology.